Loading
A phase 2 trial of FES PET in Breast cancer, run by Hoag Memorial Hospital Presbyterian, with a status the registry has not verified recently.
18F-fluoroestradiol (FES) PET/CT for Breast Cancer is a phase 2 interventional study registered as NCT04883814 by Hoag Memorial Hospital Presbyterian, with 124 participants planned, started 2021-01-15 and due to reach its primary completion in 2023-12-15. Interventions recorded: 18F-fluoroestradiol PET/CT. Conditions recorded: Breast Cancer.
Linked to the technology FES PET because the registry names it ("18f fluoroestradiol pet") among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fluoroestradiol F-18 (FES PET), FES, Breast cancer (all types) and the tag pipeline.
Shares Fluoroestradiol F-18 (FES PET), FES, Breast cancer (all types) and the tag pipeline.
Shares FES, FES PET (oestrogen receptor imaging), Breast cancer (all types) and the tag pipeline.
Shares Fluoroestradiol F-18 (FES PET), FES, Breast cancer (all types) and the tag pipeline.
Shares FES, FES PET (oestrogen receptor imaging), Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Shares Breast cancer (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/